The feasibility of stereotactic body radiotherapy (SBRT) for centrally located tumors is controversial. SBRT with 100 Gy or higher biologically equivalent dose using an α/β of 10 Gy for centrally located primary NSCLC offered excellent local control (3years; 77.6% [95% confidential interval, 65.2-86.5]), comparable with that of other SBRT reports for peripheral lung tumors. The pooled rate of Grade ≥3 complications was 12.0%. This suggest that SBRT can be used in inoperable centrally located lung tumors with a curative intent.
- Dose fractionation
- Network meta-analysis
- Non–small-cell lung carcinoma
- Survival rate
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
- Cancer Research